Bayesian Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bayesian Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-37,400	Closed	-$693K	–	1092
2023 Q3	$693K	Buy	+37,400	New	+$423K	0.08%	292
2019 Q3	–	Sell	-5,402	Closed	-$430K	–	734
2019 Q2	$430K	Buy	5,402 +400	+8%	+$35.8K	0.09%	293
2019 Q1	$560K	Buy	+5,002	New	+$547K	0.11%	260
2017 Q4	–	Sell	-4,300	Closed	-$250K	–	762
2017 Q3	$250K	Buy	4,300 +1,800	+72%	+$194K	0.06%	399
2017 Q2	$303K	Buy	+2,500	New	+$290K	0.11%	287

Bayesian Capital Management's ICPT Position: Q4 2023 in Review

Bayesian Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 37,400 shares — an estimated $693K sold.

Bayesian Capital Management first reported a position in ICPT in Q2 2017 and held it in 5 quarters. The position peaked at $693K in Q3 2023. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

Bayesian Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Bayesian Capital Management sold 37,400 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $693K.
Bayesian Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2017 and held it in 5 quarters.
Bayesian Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $693K in Q3 2023.
0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.